NASDAQ:BGLC BioNexus Gene Lab (BGLC) Stock Price, News & Analysis $1.32 0.00 (0.00%) Closing price 07/31/2026 03:58 PM EasternExtended Trading$1.26 -0.06 (-4.47%) As of 07/31/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About BioNexus Gene Lab Stock (NASDAQ:BGLC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioNexus Gene Lab alerts:Sign Up Key Stats Today's Range$1.27▼$1.3750-Day Range$1.32▼$2.6152-Week Range$1.07▼$7.21Volume10,006 shsAverage Volume10,007 shsMarket Capitalization$3.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia. Read More BioNexus Gene Lab Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreBGLC MarketRank™: BioNexus Gene Lab scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBioNexus Gene Lab has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBioNexus Gene Lab has only been the subject of 1 research reports in the past 90 days.Read more about BioNexus Gene Lab's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNexus Gene Lab is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNexus Gene Lab is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioNexus Gene Lab has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.14% of the float of BioNexus Gene Lab has been sold short.Short Interest Ratio / Days to CoverBioNexus Gene Lab has a short interest ratio ("days to cover") of 0.63, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioNexus Gene Lab has recently decreased by 76.08%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioNexus Gene Lab does not currently pay a dividend.Dividend GrowthBioNexus Gene Lab does not have a long track record of dividend growth. News and Social Media2.5 / 5News SentimentN/A News SentimentBioNexus Gene Lab has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Industrials companies.News Coverage This WeekMarketBeat has tracked 1 news article for BioNexus Gene Lab this week, compared to 2 articles on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioNexus Gene Lab insiders have not sold or bought any company stock.Percentage Held by Insiders0.05% of the stock of BioNexus Gene Lab is held by insiders.Percentage Held by Institutions18.85% of the stock of BioNexus Gene Lab is held by institutions.Read more about BioNexus Gene Lab's insider trading history. Receive BGLC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNexus Gene Lab and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BGLC Stock News HeadlinesBioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working VisitJuly 28, 2026 | globenewswire.comBioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-DevelopmentMay 29, 2026 | globenewswire.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.August 1 at 1:00 AM | Chaikin Analytics (Ad)BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard ...March 11, 2026 | markets.businessinsider.comBioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion DiagnosticsMarch 11, 2026 | quiverquant.comQBioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD PlatformMarch 11, 2026 | globenewswire.comBioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as ChairmanFebruary 23, 2026 | globenewswire.comBioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar MarketJanuary 30, 2026 | markets.businessinsider.comSee More Headlines BGLC Stock Analysis - Frequently Asked Questions How have BGLC shares performed this year? BioNexus Gene Lab's stock was trading at $4.1150 at the start of the year. Since then, BGLC stock has decreased by 67.9% and is now trading at $1.32. How were BioNexus Gene Lab's earnings last quarter? BioNexus Gene Lab Corp. (NASDAQ:BGLC) released its quarterly earnings results on Friday, May, 15th. The company reported ($0.23) earnings per share for the quarter. The firm earned $0.02 million during the quarter. BioNexus Gene Lab had a negative net margin of 54.70% and a negative trailing twelve-month return on equity of 37.43%. When did BioNexus Gene Lab's stock split? BioNexus Gene Lab shares reverse split on the morning of Monday, April 7th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, April 6th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did BioNexus Gene Lab IPO? BioNexus Gene Lab (BGLC) raised $5 million in an IPO on Thursday, July 20th 2023. The company issued 1,300,000 shares at a price of $4.00 per share. Network 1 Financial Securities served as the underwriter for the IPO. How do I buy shares of BioNexus Gene Lab? Shares of BGLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioNexus Gene Lab own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioNexus Gene Lab investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings5/15/2026Today8/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (12m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 BGLC's financial health is in the Yellow zone, according to TradeSmith. BGLC has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorIndustrials Industry Trading Companies & Distributors Sub-IndustryTrading Companies & Distributors Current SymbolNASDAQ:BGLC CIK1737523 Webwww.bionexusgenelab.com Phone60-1-2212-6512FaxN/AEmployees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.98 million Net Margins-54.70% Pretax Margin-54.72% Return on Equity-37.43% Return on Assets-32.88% Debt Debt-to-Equity Ratio0.01 Current Ratio6.53 Quick Ratio5.69 Sales & Book Value Annual Sales$7.43 million Price / Sales0.43 Cash FlowN/A Price / Cash FlowN/A Book Value$3.56 per share Price / Book0.37Miscellaneous Outstanding Shares2,420,000Free Float2,416,000Market Cap$3.19 million OptionableNot Optionable Beta4.08 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:BGLC) was last updated on 8/1/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored“The unseen winner of the AI race” is not SpaceXMarc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...Chaikin Analytics | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNexus Gene Lab Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNexus Gene Lab With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
